↓ Skip to main content

American Association for Cancer Research

Article Metrics

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

Overview of attention for article published in Molecular Cancer Therapeutics, December 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
17 tweeters

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
11 Mendeley
Title
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Published in
Molecular Cancer Therapeutics, December 2021
DOI 10.1158/1535-7163.mct-21-0615
Pubmed ID
Authors

Anne Roulston, Michal Zimmermann, Robert Papp, Alexander Skeldon, Charles Pellerin, Émilie Dumas-Bérube, Valerie Dumais, Stéphane Dorich, Lee D. Fader, Sara Fournier, Li, Marie-Eve Leclaire, Shou Yun Yin, Amandine Chefson, Hunain Alam, William Yang, Chloe Fugère-Desjardins, Sabrina Vignini-Hammond, Kathryn Skorey, Amina Mulani, Victoria Rimkunas, Artur Veloso, Martine Hamel, Rino Stocco, Yael Mamane, Zuomei Li, Jordan T.F. Young, Michael Zinda, W. Cameron Black

Twitter Demographics

The data shown below were collected from the profiles of 17 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 64%
Student > Bachelor 1 9%
Unknown 3 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 45%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Agricultural and Biological Sciences 1 9%
Medicine and Dentistry 1 9%
Unknown 3 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2022.
All research outputs
#2,629,713
of 21,152,972 outputs
Outputs from Molecular Cancer Therapeutics
#370
of 3,581 outputs
Outputs of similar age
#76,249
of 452,844 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#5
of 43 outputs
Altmetric has tracked 21,152,972 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,581 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,844 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.